A Moving Target: Impacts of Lowering Viral Load Suppression **Cutpoints on Progress Towards HIV Epidemic Control Goals**

Joseph G. ROSEN¹*, Steven J. REYNOLDS^{2,3,4}, Ronald M. GALIWANGO², Godfrey KIGOZI², Thomas C. QUINN^{2,3,4}, Oliver RATMANN⁵, Anthony NDYANABO², Lisa J. NELSON⁶, Gertrude NAKIGOZI², Margaret NALUGEMWA², Katherine B. RUCINSKI¹, Caitlin E. KENNEDY^{1,2}, Larry W. CHANG^{1,2,3}, Joseph KAGAAYI², David SERWADDA², M. Kate GRABOWSKI^{2,7,8}

¹ Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

² Rakai Health Sciences Program, Entebbe, Uganda

³ Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD, USA

⁴ Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA

⁵ Department of Mathematics, Imperial College, London, United Kingdom

⁶ Centers for Disease Control and Prevention, Kampala, Uganda

⁷ Division of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA

⁸ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

Running Head: Lowering VLS Cutpoints in Rakai, Uganda

*Corresponding author: Joseph G. Rosen, 615 N. Wolfe Street, E5031, Baltimore, MD 21202 T: +1 (305) 331-5568 | F: +1 (410) 614-7553 | E: jrosen72@jhu.edu

Conflicts of Interest

The authors have no conflicts of interest to disclose.

Funding

This study was supported by the National Institute of Allergy and Infectious Diseases (NIAID) (U01AI100031, U01AI075115, R01AI110324, R01AI128779, R01AI123002, R01AI143333, R01AI55080, T32AI102623); the National Institute of Mental Health (R01MH105313); the Division of Intramural Research of the NIAID; and the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) under the terms of NU2GGH000817. JGR and KBR were supported by the National Institute of Mental Health (F31MH126796, K01MH129226). The content is solely the responsibility of the authors and does not necessarily reflect the official views of the funding agencies.

Ethical Statement

The study was approved by the Uganda Virus Research Institute Research and Ethics Committee and the Johns Hopkins University School of Medicine Institutional Review Board. This project was reviewed in accordance with CDC human research protection procedures and was determined to be research, but CDC investigators did not interact with human subjects or have access to identifiable data or specimens for research purposes.

Word Count: 989/1,000

1 Summary

- Redefining viral load suppression (VLS) using lower cutpoints could impact progress towards
 the UNAIDS 95-95-95 targets. We assessed impacts of lowering the VLS cutpoint on achieving
 the 95-95-95 VLS target in the Rakai Community Cohort Study. Population VLS fell from 86%
 to 84% and 76%, respectively, after lowering VLS cutpoints from <1,000 to <200 and <50
 copies/mL. The fraction of viremic persons increased by 17% after lowering the VLS cutpoint
 from <1,000 to <200 copies/mL.
- 8 Key Words: viral load suppression, viral load cutpoint, Fast-Track targets, population-based
- 9 study, Uganda

10 The 95-95-95 Fast-Track targets proposed by the Joint United Nations Programme on 11 HIV/AIDS (UNAIDS) are ambitious goals for HIV elimination by 2030.¹ To reach the "third 12 95", 86% of people living with HIV (95% of whom are receiving antiretroviral therapy (ART)) 13 must achieve viral load suppression (VLS). The World Health Organization (WHO) defines VLS 14 as <1,000 RNA copies/mL,² a threshold associated with reduced HIV transmission risk.^{3,4} This 15 definition is also used by national surveys in Africa, including the population-based HIV impact 16 assessments.⁵

A VLS cutpoint of <1,000 copies/mL, however, potentially underestimates the proportion of individuals on ART experiencing negative consequences of viremia. A study in Lesotho estimated that 94% of treatment-experienced persons with viral loads 80-999 copies/mL harbored drug-resistant mutations.⁶ Likewise, persistent low-level viremia (50-999 copies/mL over ≥ 6 months) has been linked to subsequent virologic failure and drug resistance.⁷ These findings, coupled with rising levels of HIV drug resistance across Africa, have prompted calls to redefine VLS using lower cutpoints.^{8,9}

24 In addition to identifying persistent low-level viremia of potential clinical significance, 25 lowering VLS cutpoints will also result in the detection and escalated management of people 26 experiencing clinically insignificant transient viremia, or viral "blips". Emerging evidence also 27 suggests viremic blips of low magnitude (<500 copies/mL) unassociated with subsequent virologic failure are common in persons with prolonged ART use.¹⁰ Implementing more 28 29 conservative VLS cutpoints could, therefore, prompt unwarranted switching of suppressed 30 persons to second- or third-line ART regimens, which remain scarce in many higher-burden countries.¹¹ Lowering existing VLS cutpoints could also increase the proportion of people on 31

32 ART requiring enhanced clinical monitoring and intensive adherence support, which could33 further strain already under-resourced health systems in hyperendemic settings.

34 To assess the impact of using different VLS cutpoints in estimating progress towards the 35 95-95-95 targets, we used data from the Rakai Community Cohort Study (RCCS), an open, population-based prospective study of 40 communities in south-central Uganda.¹² After 36 37 providing written informed consent, RCCS participants undergo rapid HIV testing using a validated three-test algorithm followed by confirmatory enzyme immunoassays,¹³ and viral load 38 39 testing is performed on stored plasma using the Abbott RealTime HIV-1 assay (Abbott 40 Molecular, Inc., Des Plaines, IL). We estimated VLS by calculating the proportion of persons with undetectable viral loads or exhibiting viremia below specific cutpoints over three survey 41 42 intervals: February 2015 to September 2016 (midpoint: November 2015), October 2016 to May 2018 (midpoint: July 2017), and June 2018 to October 2020 (midpoint: August 2019). 43

44 First, we estimated population viral load among persons with detectable viremia (\geq 50 45 copies/mL) and ART coverage (prevalence of self-reported ART use), respectively. We used 46 Wilcoxon rank-sum tests to evaluate whether observed changes in population viral load over 47 time were statistically significant (p < 0.05). Next, to evaluate the impact of VLS cutpoints on 48 Fast-Track target achievement, we ascertained the sensitivity of population VLS estimates 49 against four different VLS cutpoints: <1,000, <400, <200, and <50 copies/mL (the latter 50 approaching the lower limit of detection for many viral load assays). Lastly, among persons with 51 detectable viremia, we examined the distribution of viral copy counts to estimate the relative 52 increase in the fraction of unsuppressed persons if VLS cutpoints were lowered.

53 Overall, 5,814 individuals (median age: 33 years, 63% women) contributed 10,418 54 observations over three survey intervals (2015: n=3,606, 2017: n=3,590, 2019: n=3,222). Across

4

cutpoints (Figure 1A), population VLS increased significantly over time, with detectable
viremia declining from a median of 9,136 copies/mL (interquartile range [IQR] 2,467-34,434) in
2015 to 2,516 copies/mL (IQR 150-22,101) in 2019 (*p*<0.001). These reductions in population
viremia coincided with substantial increases in ART coverage, from 67% (95% confidence
interval [CI] 65-68%) in 2015 to 85% (CI 83-86%) in 2019.

By 2019, population VLS met the 95-95-95 target using a cutpoint of <1,000 copies/mL (86%, CI 85-87%). However, when using the most conservative cutpoint of <50 copies/mL, population VLS declined to 76% (CI 74-77%). When restricted to persons reporting ART use (*n*=2,725), population VLS remained below the 95% target (83%, CI 82-85%) when using a cutpoint of <50 copies/mL. Among persons with detectable viremia in 2019 (*n*=788), lowering the VLS cutpoint from <1,000 to <200 copies/mL would increase the proportion of unsuppressed persons by 17% (**Figure 1B**).

67 Our study provides evidence that estimates of the "third 95" at a population level are 68 highly sensitive to VLS cutpoints. Relative to a more conservative clinical VLS cutpoint of <5069 copies/mL, a cutpoint of <1,000 copies/mL, per WHO recommendations, overestimated 95-95-70 95 Fast-Track target achievement in our sample by ~10% on an absolute scale. This relationship 71 persisted even after restricting population VLS measures to persons reporting ART use. 72 Lowering VLS cutpoints would, therefore, require reassessment of countries and subnational 73 units meeting the "third 95" using a <1,000 copies/mL cutpoint. Multilateral agencies and donors 74 must be prepared to articulate justifications for lowering VLS cutpoints and manage expectations 75 surrounding revisions to Fast-Track target achievement, ensuring investments in HIV treatment 76 programs are sustained, rather than abandoned, if progress towards the "third 95" is revisited.

77 Furthermore, we found that by lowering the VLS cutpoint from <1,000 to <200 78 copies/mL, the fraction of persons classified as unsuppressed increased by 17%. This would 79 represent a substantial population-level increase in the number of individuals requiring enhanced 80 clinical monitoring (e.g., intensive ART adherence support, increased care appointment 81 frequency). While vigilance around lower-level viremia may be clinically indicated, the abrupt 82 growth in persons requiring enhanced clinical support may be challenging for health systems to 83 manage without additional resources and investments. Updated clinical guidelines with 84 algorithms for switching individuals to second- or third-line ART in the context of persistent 85 lower-level viremia are also warranted.

Irrespective of VLS cutpoints, our findings highlight remarkable achievements in HIV epidemic control, largely attributable to the scale-up of combination HIV interventions and universal ART provision in south-central Uganda.¹⁴ Continued transitioning of persons stable on ART to differentiated service delivery models, coupled with promising testing and treatment technologies in the development pipeline (i.e., long-acting ART, point-of-care viral load assays), may accelerate momentum towards HIV elimination in this setting.

92 Acknowledgements

93 We extend our gratitude to the Rakai Community Cohort Study participants, mobilizers, 94 enumerators, data management staff, and community leaders-without whom this study would 95 not be possible. JGR, SJR, GK, TCQ, OR, GN, MN, KBR, CEK, LWC, JK, DS, and MKG conceptualized and designed the study. SJR, RMG, GK, TCQ, GN, MN, LWC, JK, DS, and 96 97 MKG oversaw data collection and laboratory testing. AN oversaw data management. JGR 98 conducted data analysis, with input from KBR, CEK, LWC, and MKG. JGR prepared the first 99 draft of the manuscript. All authors reviewed, contributed to, and approved the final manuscript 100 submitted for publication.

101 References

- 102 1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Fast-Track: Ending the AIDS
- 103 *Epidemic by 2030.* UNAIDS; 2014.
- 104 https://www.unaids.org/sites/default/files/media_asset/JC2686_WAD2014report_en.pdf
- 105 2. World Health Organization. Consolidated Guidelines on HIV Prevention, Testing,
- 106 *Treatment, Service Delivery and Monitoring: Recommendations for a Public Health*
- 107 *Approach*. WHO; 2021. https://www.who.int/publications/i/item/9789240031593
- 108 3. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral Load and Heterosexual Transmission of
- 109 Human Immunodeficiency Virus Type 1. *New England Journal of Medicine*.
- 110 2000;342(13):921-929. doi:10.1056/NEJM200003303421303
- 111 4. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act
- in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. *Lancet*.
- 113 2001;357(9263):1149-1153. doi:10.1016/S0140-6736(00)04331-2
- 114 5. Justman JE, Mugurungi O, El-Sadr WM. HIV Population Surveys Bringing Precision to
- the Global Response. *N Engl J Med.* 2018;378(20):1859-1861.
- doi:10.1056/NEJMp1801934
- 117 6. Labhardt ND, Bader J, Lejone TI, et al. Should viral load thresholds be lowered?:
- 118 Revisiting the WHO definition for virologic failure in patients on antiretroviral therapy in
- resource-limited settings. *Medicine*. 2016;95(28):e3985.
- doi:10.1097/MD.00000000003985
- 121 7. Taiwo B, Gallien S, Aga E, et al. Antiretroviral Drug Resistance in HIV-1–Infected Patients
- 122 Experiencing Persistent Low-Level Viremia During First-Line Therapy. J Infect Dis.
- 123 2011;204(4):515-520. doi:10.1093/infdis/jir353

	Emerging Threat to Epidemic Control.
--	--------------------------------------

- 125 *New England Journal of Medicine*. 2017;377(17):1605-1607. doi:10.1056/NEJMp1710608
- 126 9. de Waal R, Lessells R, Hauser A, et al. HIV drug resistance in sub-Saharan Africa: public
- health questions and the potential role of real-world data and mathematical modelling. *J*
- 128 *Virus Erad.* 2018;4(Suppl 2):55-58.
- 129 10. Grennan JT, Loutfy MR, Su D, et al. Magnitude of virologic blips is associated with a
- 130 higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J
- 131 Infect Dis. 2012;205(8):1230-1238. doi:10.1093/infdis/jis104
- 132 11. Madec Y, Leroy S, Rey-Cuille MA, Huber F, Calmy A. Persistent difficulties in switching
- to second-line ART in sub-saharan Africa--a systematic review and meta-analysis. *PLoS*

134 *One*. 2013;8(12):e82724. doi:10.1371/journal.pone.0082724

- 135 12. Chang LW, Grabowski MK, Ssekubugu R, et al. Heterogeneity of the HIV epidemic in
- agrarian, trading, and fishing communities in Rakai, Uganda: an observational
- 137 epidemiological study. *Lancet HIV*. 2016;3(8):e388-e396. doi:10.1016/S2352-
- 138 3018(16)30034-0
- 139 13. Galiwango RM, Musoke R, Lubyayi L, et al. Evaluation of current rapid HIV test

algorithms in Rakai, Uganda. *J Virol Methods*. 2013;192(1-2):25-27.

- 141 doi:10.1016/j.jviromet.2013.04.003
- 142 14. Grabowski MK, Serwadda DM, Gray RH, et al. Combination HIV Prevention and HIV
- 143 Incidence in Uganda. *N Engl J Med*. 2017;377(22):2154-2166.
- 144 doi:10.1056/NEJMoa1702150

Figure 1. Viral load suppression prevalence (Panel A) and the distribution of viral copy counts among viremic (\geq 50 copies/mL) persons living with HIV (Panel B), by calendar period.

